Aureate Tradde IPO is a SME IPO of 38,98,000 equity shares of the face value of ₹10 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is . The Aureate Tradde IPO open and close dates are not available as of now. MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Molbio Diagnostics IPO Details Details
Molbio Diagnostics IPO is a book-built issue worth ₹939.70 crore, comprising a fresh issue of 0.25 crore equity shares aggregating to ₹200.00 crore and an offer for sale (OFS) of 0.92 crore equity shares aggregating to ₹739.70 crore. The IPO will open for subscription on August 10, 2026, and close on August 12, 2026. The basis of allotment is expected to be finalized on August 13, 2026, while the company's shares are tentatively scheduled to be listed on the NSE and BSE on August 17, 2026. The price band for the IPO has been fixed at ₹768–₹807 per equity share. Investors can apply in lots of 18 shares, requiring a minimum investment of ₹14,526 for retail investors (calculated at the upper price band of ₹807 per share). Kotak Mahindra Capital Co. Ltd. is the Book Running Lead Manager (BRLM) for the issue, while KFin Technologies Ltd. has been appointed as the Registrar. Investors are advised to refer to the Red Herring Prospectus (RHP) for detailed information on the company, its financials, risk factors, and the IPO.
IPO Details
| IPO Date | 10 Aug 26 |
| Listing Date | 17 Aug 26 |
| Face Value | ₹1 per share |
| Price Band | ₹768 to ₹807 |
| Lot Size | 18 |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE, BSE |
| Total Issue Size | ₹940 Cr |
| Fresh Issue |
₹200 Cr
|
| Offer for Sale | |
| Share Holding Pre Issue | 11,27,59,750 shares |
| Share Holding Post Issue | 11,52,39,996 shares |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35% of the Net Offer |
| NII Shares Offered | Not less than 15% of the Net Offer |
About Molbio Diagnostics IPO Details.
Incorporated in October 2000, Molbio Diagnostics Limited is a leading global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for both infectious and non-communicable diseases.
The company's flagship innovation, the Truenat® platform, is a portable, battery-operated, PCR-based molecular diagnostic system specifically designed for resource-limited settings. It delivers highly accurate test results in less than an hour, enabling faster diagnosis and timely treatment, making it particularly valuable for decentralized healthcare environments.
Molbio offers a broad portfolio of 43 diagnostic assays covering more than 30 diseases, including Tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, Human Papillomavirus (HPV), and several other infectious diseases. In addition to molecular diagnostics, the company has expanded into radiology, digital pathology, and breast health screening through its subsidiaries and strategic partnerships. Backed by robust in-house research & development (R&D) capabilities, Molbio continues to strengthen its product pipeline with innovative diagnostic technologies.
The company operates six state-of-the-art manufacturing facilities across India and has built a strong international presence, serving customers in more than 90 countries. Its clientele includes government healthcare programs, diagnostic laboratories, hospitals, and leading international healthcare organizations. Supported by a strong portfolio of patents, global quality certifications, and strategic acquisitions, Molbio has established itself as one of the leading innovators in the global molecular diagnostics industry.
As of March 31, 2026, Molbio Diagnostics employed 1,225 permanent professionals across key functions, including research & development, manufacturing, quality assurance, sales & marketing, finance, and corporate operations, reflecting its strong operational capabilities and continued focus on innovation.
Key Strengths
Proprietary Truenat® Platform: Owns the innovative Truenat® molecular diagnostics platform, featuring WHO-endorsed TB testing technology designed for rapid, accurate, and decentralized diagnosis.
Strong Research & Development: Extensive in-house R&D capabilities supported by a robust global patent portfolio, enabling continuous product innovation and expansion.
Recurring Revenue Model: Generates stable and scalable revenues through the recurring sale of diagnostic test kits and consumables, in addition to diagnostic systems.
Global Market Presence: Operates in 90+ countries, serving a diversified customer base comprising government healthcare programs, hospitals, diagnostic laboratories, and international health organizations.
Diversified Healthcare Portfolio: Strategic acquisitions and collaborations have expanded the company's presence beyond molecular diagnostics into radiology, digital pathology, and breast health screening.
Experienced Leadership Team: Led by an experienced management team with deep expertise in molecular diagnostics, medical technology, healthcare innovation, and global commercialization.
Company Financials (Restated)
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 | |
|---|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 | |
| Total Income | 1,455.17 | 1,027.94 | 840.66 | |
| Profit After Tax | 164.14 | 138.58 | 83.54 | |
| EBITDA | 328.24 | 256.64 | 185.09 | |
| Net Worth | 1,144.68 | 952.95 | 807.94 | |
| Amount in ₹ Crore | ||||
IPO Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space. | 125.12 |
| 2 | Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and | 80.81 |
| 3 | General Corporate Purposes | 0.00 |
Key Performance Indicator (KPI)
| KPI | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| ROE | 15.59%% | 16.20%% |
| ROCE | 17.55%% | 20.98%% |
| Debt/Equity | - | - |
| RoNW | 14.55%% | 15.23%% |
| PAT Margin | 11.28%% | 13.48%% |
| EBITDA Margin | 22.56%% | 24.97%% |
Key Performance Indicator (KPI)
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 14.56 | 14.24 |
| The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2026 available in RHP. The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2026 available in RHP. | ||
IPO Registrar
- Kfin Technologies Ltd.
- 040-79615565
- molbio.ipo@kfintech.com
- Visit Website
IPO Lead Manager(s)
- Kotak Mahindra Capital Co.Ltd. .
- IIFL Capital Services Ltd. .
- Jefferies India Pvt.Ltd. .
- Motilal Oswal Investment Advisors Ltd. .
Lead Manager Reports
Contact Details
Molbio Diagnostics Ltd. Address
Plot No. L-46 Phase II-D, Verna Industrial Area Verna, Salcete South Goa, Goa, 403722
- 8326724888
- investors@molbiodiagnostics.com
- Visit Website
IPO FAQs
-
What is the Aureate Tradde IPO?
-
How to apply in Aureate Tradde IPO through Zerodha?
Zerodha customers can apply online in Aureate Tradde IPO using UPI as a payment gateway. Zerodha customers can apply in Aureate Tradde IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Aureate Tradde IPO through Zerodha
- Visit the Zerodha website and login to Console.
- Go to Portfolio and click the IPOs link.
- Go to the ' Aureate Tradde IPO ' row and click the 'Bid' button.
- Enter your UPI ID, Quantity, and Price.
- Submit IPO application form.
- Visit the UPI App (net banking or BHIM) to approve the mandate.
Visit Zerodha IPO Application Process Review for more detail.
-
When Aureate Tradde IPO will open?
The Aureate Tradde IPO dates are not announced. Please check back again after some time.
-
What is the lot size of Aureate Tradde IPO?
Aureate Tradde IPO lot size and the minimum order quantity is not available at this time. Please check again later.
-
How to apply for Aureate Tradde IPO?
You can apply in Aureate Tradde IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
-
Is online banking secure?
Repudiated and annoyances accepted the wise man therefore always holds in these matters to this principle selection he rejects pleasures to secures.
-
When is Aureate Tradde IPO allotment?
The finalization of Basis of Allotment for Aureate Tradde IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Aureate Tradde IPO allotment status.
-
When is Aureate Tradde IPO listing date ?
The Aureate Tradde IPO listing date is not yet announced. The tentative date of listing is .